Related Experiment Video
Updated: Jun 28, 2026
06:38
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
Systemic therapy for metastatic renal cell carcinoma
Glenn S Kroog1, Robert J Motzer
1Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA. kroogg@mskcc.org
The Urologic Clinics of North America
|November 11, 2008
Summary
Renal cell cancer (RCC) is a common kidney cancer. Recent advances in targeted therapies like sunitinib, sorafenib, and temsirolimus have improved patient outcomes, with ongoing research focusing on new drug development and combinations.
Area of Science:
- Oncology
- Nephrology
- Pharmacology
Background:
- Renal cell cancer (RCC) represents the most prevalent kidney cancer in the U.S., with around 44,000 annual cases.
- Historically, immunotherapy was the sole treatment demonstrating efficacy in metastatic RCC.
- Recent years have seen significant improvements in survival and quality of life for metastatic RCC patients due to a better understanding of RCC development.
Purpose of the Study:
- To summarize recent advancements in the treatment of renal cell cancer.
- To highlight the impact of newly approved targeted therapies.
- To outline current research directions for improving RCC treatment outcomes.
Main Methods:
- Review of recent clinical research and drug approvals for metastatic RCC.
- Analysis of the efficacy of targeted therapies (sunitinib, sorafenib, temsirolimus).
- Examination of ongoing research into novel drug development and combination therapies.
Main Results:
- Three targeted therapies, sunitinib, sorafenib, and temsirolimus, have been recently approved in the U.S.
- These targeted therapies represent a significant advancement over historical treatments for metastatic RCC.
- Current research is actively exploring new therapeutic agents and synergistic drug combinations.
Conclusions:
- Advances in understanding RCC development have led to improved patient survival and quality of life.
- Approved targeted therapies have transformed the treatment landscape for metastatic RCC.
- Future research efforts are focused on developing novel drugs and optimizing combination strategies to further enhance treatment efficacy.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:30Metastasis
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...